High expression of CD30 and JunB is characteristic of tumor cells in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL). Possible interactions of CD30 and JunB were examined in this study. We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)-positive and NPM-ALK-negative ALCL and HL is regulated by a constitutively active CD30-extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK). Phosphorylation of ERK1/2 MAPK was confirmed in nuclei of tumor cells in both ALCL and HL. CD30-ERK1/2 MAPK signals induce JunB expression, which maintains high activity of the CD30 promoter. JunB induction seems to be largely independent of nuclear factor KB in ALCL and HL. These results show a common mechanism of CD30 overexpression in ALCL and HL, although the outcome of CD30 signaling differs between NPM-ALK-positive ALCL and NPM-ALK-negative ALCL, cutaneous ALCL, and HL as we recently reported. (Cancer Res 2005; 65(17): 7628-34) 
Introduction
JunB is a member of the activator protein (AP-1) transcription family. AP-1 is composed of homo-or heterodimers of the related Jun (c-Jun, JunB, JunD), Fos (Fos, FosB, Fra1, Fra2) and ATF, CREB families (1) . AP-1 is involved in different biological processes including cell differentiation, proliferation, and apoptosis (2, 3) . Transcription of AP-1 family members is rapidly and transiently stimulated by multiple extracellular signals (4) . c-Jun and JunB have antagonistic functions in biological processes such as oncogenic transformation and cell proliferation. However, JunB also regulates distinct target genes in a c-Jun-independent manner and exerts specific functions (5) . Overexpression of JunB has been reported to be associated with neoplastic transformation (2, (6) (7) (8) .
Overexpression of CD30 and JunB is recognized as a common feature of Hodgkin-Reed-Sternberg (H-RS) cells and anaplastic large cell lymphoma (ALCL) cells (9) (10) (11) (12) . Recent cloning and characterization of the promoter region of the CD30 gene revealed that the CD30 promoter is composed of a microsatellite region containing CCAT repeats and a core promoter with Sp-1 binding sites. The Sp-1 site at À43 to À38 within the core promoter is responsible for maximum promoter activity (13, 14) . Repeats of the CCAT motif within the CD30 microsatellite repress core CD30 promoter activity. Thus, it was hypothesized that the CD30 microsatellite may be truncated in CD30-overexpressing cells, possibly because of microsatellite instability (14, 15) . We recently characterized the structure and function of the CD30 microsatellite from H-RS cell lines. The results showed that the CD30 microsatellite of H-RS cell lines are not truncated, and the AP-1 site (À377 to À371) located within the microsatellite relieves suppression by the microsatellite through interaction with JunB (10) . This JunB-mediated induction of CD30 promoter seems to be one mechanism underlying high levels of CD30 promoter activity in H-RS cells (10) .
In this report, we studied mechanisms underlying high levels of CD30 and JunB expression in ALCL and H-RS cells. We first examined interactions between overexpressed CD30 and JunB. Next, we investigated whether JunB-mediated induction of CD30 promoter also operates in ALCL cells. We found that CD30 signals regulate JunB expression dependent on the extracellular signalregulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK) pathway, which may act to stabilize CD30 induction in ALCL and H-RS cells. The results show that tumor cells of ALCL and Hodgkin lymphoma (HL) share a common mechanism of CD30 and JunB induction.
Materials and Methods
Cell lines and cell cultures. K562 and HEK293 cell lines were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan) and Fujisaki Cell Biology Center (Okayama, Japan). Nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)+ ALCL cell lines (SUDHL1, Karpas299, and SR786) and H-RS cell lines (HDLM2, L428, and L540) were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Mac1 is a NPM-ALK-negative cutaneous ALCL cell line (16) . Establishment of an HEK293 transformant stably overexpressing CD30 was described previously (17) . Nonadherent cell lines were cultured in RPMI 1640 and adherent cells in DMEM with supplementation of recommended concentrations of FCS and antibiotics.
Inhibitors. DHMEQ is a nuclear factor nB (NF-nB) inhibitor that acts at the level of nuclear translocation of NF-nB (18) . Inhibitors for MEK1/2 (UO126), c-Jun-NH 2 -kinase (JNK; SP600125) and p38 MAPK (SB203580), were purchased from Cell Signaling Technology (Beverly, MA), BioMol (Plymouth Meeting, PA), and Sigma (Tokyo, Japan), respectively. Compounds were dissolved with DMSO and used for experiments at specified concentrations. Northern blotting. Northern blot analysis was done essentially as described (10) . Briefly, polyadenylic acid-selected RNA was size-fractionated on 1% formalin agarose gel electrophoresis and subsequently blotted onto Hybond-C extra-nitrocellulose membranes (Amersham Bioscience, Piscataway, NJ). Filters were hybridized in 4Â SSC, 1Â Denhardt's, 0.5% SDS, 0.1 mol/L NaPO 4 (pH 7.0), 10% dextran Na at 65jC with 1.0 Â 10 6 cpm/mL of random prime-labeled probes. After washings to a final stringency of 0.2Â SSC and 0.1% SDS at 65jC, filters were exposed to XAR-5 films (Eastman Kodak, Rochester, NY) at À80jC. RT-PCR amplified cDNA fragments of human JunB and human glyceraldehyde-3-phosphate dehydrogenase were used as probes.
Immunoblot analysis. Immunoblotting experiments were done as described previously (19, 20) . Cell lysates were prepared from 1 Â 10 6 cells in a lysis buffer [10 mmol/L Tris-HCl (pH 7.4), 1% SDS, 1 mmol/L sodium orthovanadate, 0.1 mmol/L sodium molybdate, and 1 mmol/L phenylmethylsulfonyl fluoride]. Antibodies used were as follows: JunB (C-11), c-Jun (H-79), Raf-1 (E-10), and a-tubulin (TU-02; all from Santa Cruz Biotechnology, Santa Cruz, CA), total ERK1/2 MAPK, phosphorylated (p-)ERK1/2 MAPK (Thr 202 /Tyr 204 ), JNK, p38 MAPK, and p-p38 MAPK (all from Cell Signaling Technology), and CD30 (Dako, Kyoto, Japan).
Immunohistochemistry. Fluorescence immunostaining was done on cultured cells and signals were detected using confocal microscopy (Radiance 2000, Bio-Rad, Richmond, CA) as described (20, 21) . Primary antibodies used were as follows: JunB (Santa Cruz), p-ERK1/2 MAPK or total ERK1/2 MAPK (both from Cell Signaling Technology).
Immunostaining on paraffin-embedded specimens of primary ALCL and HL samples was done as described (10) . Primary antibodies used were as follows: p-ERK1/2 MAPK, total ERK1/2 MAPK (both from Cell Signaling Technology) or ALK (Immunotech, Marseille, France).
DNA constructs. Construction of various CD30 promoter-driven luciferase plasmids was described previously (10) . An AP-1 site-dependent luciferase vector p(AP-1) 7 was purchased from Stratagene (Tokyo, Japan). A JunB expression vector pME-JunB was described previously (10) . The structure of the expression vector for the dominant-negative CD30, CD30D has been described (17 Treatment of cells with actinomycin D. To measure the half-life of JunB mRNA, cells were treated with 10 Ag/mL actinomycin D, an inhibitor of RNA synthesis (Sigma). Cells were incubated for 0, 0.5, 1, 2, and 5 hours, respectively, after the addition of actinomycin D, then harvested and subjected to Northern blotting.
Electrophoretic mobility shift analysis. Electrophoretic mobility shift analysis (EMSA) was done as described (10) . Double-stranded oligonucleotides containing the AP-1 consensus sites (5V -CGCTTGATGAGTCAGCCG-GAA-3V) were purchased from Promega. The nucleotide sequence of the CD30 microsatellite AP-1 site probe is as follows: 5V -CACTCACTGATT-CATTTTACA-3V (nucleotide position À384 to À364). Nuclear extracts were prepared basically according to the method reported by Andrews and Faller (22) . Antibodies used for supershift assays are as follows: 19) , and JunD (329; all from Santa Cruz Biotechnology). Inhibition of JunB expression by small interfering RNA. Target sequences of small interfering RNA (siRNA) 5V -AATGGAACAGCCCTTC-TACCA-3V for JunB were described previously (10) . Twenty picomoles of siRNAs were transduced into 2 Â 10 5 of Karpas299, SUDHL1, and K562 and 1 Â 10 5 of HEK 293 cells by LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instruction. Cells were plated and maintained in appropriate conditions and used in the following experiments. The scrambled oligonucleotide 5V -CATGCTTAAATGGGCCCATGA-3V was served as a control.
Results
CD30 signals induce JunB expression in anaplastic large cell lymphoma and Hodgkin-Reed-Sternberg cell lines. Overexpression of CD30 and JunB is a common feature of tumor cells in ALCL and HL cells (9) (10) (11) (12) . We decided to test the hypothesis that CD30 and JunB regulation are interrelated in these lymphomas. We first used a HEK293 transformant that highly expresses CD30 (293CD30; ref. 17) . Northern blot analysis showed significantly increased JunB transcripts in 293CD30 cells compared with that in parental HEK293 cells (Fig. 1A, a) . Induction of JunB protein in 293CD30 cells was shown by confocal immunofluorescence microscopy and immunoblot analysis (Fig. 1A, b and c) . In reporter gene assays, cotransfection of a CD30 expression vector resulted in activation of the JunB promoter in HEK293 cells, although the magnitude was not great (Fig. 1B) . Cotransfection of CD30D inhibited JunB promoter induction by CD30 overexpression (Fig. 1B) . These results suggest that signals triggered by overexpressed CD30 can induce JunB expression in 293 cells.
To confirm that CD30 signal-dependent induction of JunB actually occurs in ALCL and H-RS cell lines, we tested whether blockade of signaling from overexpressed CD30 abrogates induction of JunB expression in these cells. We transfected a CD30D expression vector into ALCL and H-RS cell lines and studied levels of promoter activity and JunB expression. Results of reporter gene assay and confocal immunofluorescence microscopy showed down-regulation of JunB promoter activity and expression in cells transduced with FLAG-tagged CD30D (Fig. 1C, a and b) . Collectively, these results provide evidence for CD30 signal-mediated induction of JunB expression in ALCL and H-RS cells.
Induction of JunB expression is not nuclear factor-KBdependent in anaplastic large cell lymphoma and HodgkinReed-Sternberg cell lines. We next tried to clarify the CD30 signal pathway leading to induction of JunB in ALCL and H-RS cells. A recent report suggested that NF-nB is involved in the induction of JunB (11, 23, 24) . We showed that high levels of CD30 expression could drive constitutive NF-nB activation in H-RS cells (17) . Therefore, we hypothesized that CD30-mediated JunB induction is NF-nB dependent. To test this hypothesis, we compared NF-nB activation and JunB expression in ALCL and H-RS cell lines. Activation of NF-nB and expression of JunB were examined by EMSA and by immunoblot analysis, respectively. The results clearly showed abundant JunB expression in the absence of NF-nB activation in ALCL cell lines ( Fig. 2A) . Abundant JunB expression in ALCL and H-RS cell lines was also detected by Northern blot analysis (data not shown). Blockade of NF-nB activity by DHMEQ did not affect JunB protein and mRNA expression. (Fig. 2B) . The very short half-life of JunB mRNA excludes the possibility that the above result is due to a long JunB half-life (Fig. 2C) . These results indicate that high levels of JunB expression are independent of NF-nB activation in ALCL and H-RS cells, and suggest the possibility that CD30 signals other than NF-nB activation are involved in the induction of JunB expression in these cells.
Constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in induction of JunB. We next tried to elucidate the common signals that induce JunB depending on CD30 overexpression in ALCL and H-RS cells. MAPKs are evolutionary conserved serine/ threonine kinases connecting cell-surface receptors to critical targets within cells. Previous reports suggest that CD30 signals can also activate ERK1/2 MAPK, JNK, and p38MAPK pathways (25, 26) . We therefore examined the effects of inhibitors of MAPK pathways on JunB expression in ALCL and H-RS cell lines. The results showed suppression of JunB expression by MEK1/2 inhibitor UO126. Inhibition of constitutively active phosphorylation of ERK1/ 2 MAPK was confirmed by immunoblot using phosphospecific antibodies for ERK1/2 MAPK in these cells (Fig. 3A) . Under the same experimental conditions, p38 MAPK inhibitor SB203580 (10-50 Amol/L) and JNK inhibitor SP600125 (10-50 Amol/L) did not In the ERK1/2 MAPK pathway, activation of cell surface receptors is transduced by the Ras-Raf-1-ERK kinase (MEK)-ERK1/2 signal cascade and phosphorylates target transcription factors. Therefore, to further investigate the CD30-JunB pathway, we examined the involvement of Raf-1 in CD30-mediated JunB promoter activation. Transduction of a constitutively active form of Raf1 (DRaf-1) activated the JunB promoter and CD30 signals enhanced Raf-1-mediated induction of the JunB promoter (Fig. 3B) . We next directly examined expression of p-ERK1/2 by immunohistochemistry in 293CD30 cells. The result shows strong nuclear localized staining of p-ERK1/2 in 293CD30 compared with control 293vec cells (Fig. 3C) . Together, these results suggest that the ERK1/2 MAPK pathway is involved in the CD30-mediated induction of JunB in ALCL and H-RS cell lines.
Because overexpression of CD30 and JunB is reported to be a hallmark of H-RS and ALCL cells in vivo as well, we examined expression of p-ERK1/2 MAPK and total ERK1/2 MAPK in primary samples of ALCL and HL. Five samples of ALCL (ALK+), ALCL (ALKÀ) and HL examined showed restricted expression of p-ERK1/2 MAPK in tumor cell components, which was largely localized within the nucleus. Total ERK1/2 MAPK was expressed ubiquitously in lymph node cells and was predominantly localized within the cytoplasm. A primary breast cancer sample served as a positive control, p-ERK and total ERK showed the same expression pattern as those in ALCL and HL samples. Representative results are shown in Fig. 3D . Collectively, these results suggest involvement of the CD30-ERK1/2 MAPK pathway in the induction of JunB in ALCL and H-RS cells in vivo.
Strong and constitutive activator protein binding activity in anaplastic large cell lymphoma cell lines consists of JunB. We recently showed that strong and constitutive AP-1 binding activities consisting of JunB contributed to the high CD30 promoter activity through the AP-1 site in H-RS cells. Thus, we examined if this mechanism also operates in ALCL cells. We first investigated the binding activity for AP-1 in ALCL cell lines. EMSA analysis revealed that ALCL cell lines, like H-RS cell lines, show constitutively strong binding activity of AP-1, whereas other cell lines unrelated to H-RS or ALCL cells do not show significant AP-1 binding activity (Fig. 4A,  left) . AP-1 binding activity was very weak in K562 and absent in HEK293. Competition assays using SUDHL1 nuclear extracts and an unlabeled consensus probe clearly inhibited binding activity of AP-1, and an unlabeled oligomer spanning the AP-1 binding sequence in the CD30 promoter also inhibited binding of AP-1 (Fig. 4A, right) .
To clarify the components of the AP-1 binding activity of ALCL cells, supershift analyses were done using nuclear extracts of three NPM-ALK-positive ALCL cell lines, SUDHL1, Karpas299, SR786, and NPM-ALK-negative cutaneous ALCL line, Mac1, as well as antibodies for AP-1 family transcription factors. The results showed a complete shift when anti-JunB antibody was used, whereas no other antibodies showed significant shifted bands (Fig. 4B, top) . Nuclear extracts of an H-RS cell line L540 showed the same results, as we recently reported (Fig. 4B, bottom) . Immunoblot analysis revealed constitutive expression of c-Jun and JunB in ALCL and H-RS cell lines. Although c-Jun was expressed ubiquitously, JunB expression was restricted to ALCL and H-RS cells (Fig. 4C, top and middle) . These results suggest that the AP-1 binding complex of ALCL cells is localized in JunB, which is the same result as we recently reported in H-RS cell lines (10) .
JunB activates CD30 promoter through the activator protein site in anaplastic large cell lymphoma cell lines. We next studied the role of JunB in driving CD30 promoter activity in ALCL cell lines. Introduction of a mutation in the AP-1 site significantly decreased the promoter activities in SUDHL1, Karpas299, and Mac1 cells, whereas it did not do so in K562 and HEK293 cell lines unrelated to ALCL (Fig. 5A) . The decreased CD30 promoter activity caused by the introduction of a mutation in the AP-1 site was also observed when we used another ALCL cell line SR786 (data not shown).
We next wanted to test whether JunB drives the CD30 promoter through binding to the AP-1 site. Transient reporter gene assays were done using ALCL cell lines and a JunB expression vector. c-Jun expression vector served as a control. Luciferase activities driven by the wild-type CD30 promoter were activated by transduction of JunB, whereas those driven by the promoter with an AP-1 mutation were not. Moreover, transduction of c-Jun did not activate the CD30 promoter (Fig. 5B) . The relatively small activation observed in SUDHL1 and L428 cells compared with that in K562 cells may be due to higher basal levels of JunB expression in the former (10) .
Luciferase activities driven by the CD30 promoter were suppressed in ALCL cell lines by repression of endogenous JunB with siRNA as we recently reported in H-RS cell lines (Fig. 5C ). Modest reduction of CD30 promoter activity by JunB siRNA in K562 cells but not in 293 cells seems to be consistent with the previous observation that K562 cells show weak JunB expression and AP-1 activity compared with control 293 cells (10) .
Collectively, these results provide evidence that the AP-1 site is functionally responsive to JunB, but not to c-Jun, and JunB expression contributes to high CD30 promoter activities not only in H-RS cell lines but also in ALCL cell lines.
Discussion
Although there is accumulating evidence that ALCL and HL are biologically distinct, there are common features such as the high level of CD30 and JunB expression in both ALCL and H-RS cells (9) (10) (11) (12) . The mechanisms responsible for the constitutive high levels of CD30 and JunB expression seem to be essential to the pathogenesis of ALCL and HL. We reported that overexpression of CD30 could transduce constitutive signals by ligand-independent receptor aggregation (17) . Therefore, we wanted to know whether overexpressed CD30 could induce constitutive JunB expression. Because we recently reported that JunB enhances CD30 promoter activity in H-RS cells, we wanted to examine whether this mechanism also operates in ALCL. Here, we present data that supports the existence of an autoregulatory mechanism by which levels of the CD30 promoter activity are controlled by self-activated CD30-ERK1/2-JunB signaling in both ALCL and H-RS cells.
Since we found that ligand-independent signaling from overexpressed CD30 triggers constitutive activation of NF-nB in H-RS cells and others reported that multiple NF-nB sites in the promoter regulate expression of JunB (11, 23, 24) , we tested the possibility that an autonomous CD30-NF-nB-JunB loop maintains CD30 overexpression in ALCL and H-RS cells through an NF-nB-dependent mechanism. Surprisingly, the results showed that irrespective of the presence or absence of NF-nB activation, JunB expression is shown both in ALCL and H-RS cell lines ( Fig. 2A) . Moreover, blockade of NF-nB activation by a NF-nB inhibitor did not significantly reduce JunB transcripts or CD30 promoter activity in H-RS cell lines (Fig. 2B) . Furthermore, it was shown that an atypical H-RS cell line, HDMYZ, does not express CD30 and lacks JunB expression in the presence of NF-nB activation (11) . Collectively, these results indicate that JunB expression is dependent on CD30 signaling but not primarily on NF-nB activation.
Our results present direct evidence for the existence of a constitutively active CD30-ERK1/2 MAPK-JunB pathway in ALCL and H-RS cell lines and show that this mechanism operates in vivo (Fig. 3) . Our study further shows that the ERK1/2 MAPK pathway is involved in CD30 promoter regulation in these cells. Recent reports indicate the importance of the ERK1/2 MAPK pathway in the growth of H-RS and ALCL cells and suggest that inhibition of this pathway may have therapeutic value in HL. Our study confirms the importance of this pathway as a possible therapeutic target in HL and extends it to ALCL (27, 28) .
Other studies showing that CD30 signals activate the ERK1/2 MAPK pathway and that ERK1/2 MAPK activates the JunB promoter support our conclusion that JunB expression is regulated by the CD30-ERK1/2 MAPK pathway (29, 30) . Previous reports suggest that CD30 signals can activate ERK1/2 MAPK, JNK, and p38MAPK pathways (25, 26) . We reported that NPM-ALK oncoprotein abrogates CD30-mediated activation of NF-nB by direct interaction with TRAF proteins in ALCL cells. JNK and p38MAPK transduce signals depending on TRAF proteins and these pathways also seem to be interrupted by NPM-ALK oncoprotein in ALCL cells (21) . These observations support the notion that the CD30-ERK1/2 MAPK-JunB pathway functions similarly in ALCL and H-RS cells.
We reported that it is not the truncation of the microsatellite but JunB-mediated relief of suppression by the microsatellite which is a mechanism underlying high levels of CD30 promoter activity in H-RS cells (10) . Our observations also revealed the absence of truncation of the microsatellite in the CD30 promoter in ALCL cell lines Karpas299, SUDHL1, and SR786. 7 Because the repressive activity of the microsatellite is thought to be mediated by binding of protein(s) to CCAT repeats within the microsatellite, this finding suggests that high levels of CD30 expression in ALCL cells cannot be ascribed only to alleviation of the repressive activity of the microsatellite by reduction of the CCAT repeat number. The results here show that JunB can activate the CD30 promoter through the AP-1 site in ALCL cells. These findings indicate that the same regulatory mechanisms of CD30 promoter induction operate in both ALCL and H-RS cells.
Our study shows that JunB is the major AP-1 binding component in ALCL cells, and JunB, but not c-Jun, can activate the CD30 promoter. These results substantiate the regulatory function of JunB in ALCL and H-RS cells. Although JunB has been thought to be less active and antagonize c-Jun (2, (31) (32) (33) (34) , recent reports suggest that JunB also regulates distinct target genes in a c-Jun-independent manner (5-8). Thus, in spite of constitutive expression of JunB and c-Jun in ALCL and H-RS cells, JunB seems to be the principal molecule that drives the CD30 promoter through the AP-1 site. However, our results do not exclude the possibility that molecule(s) other than JunB are also involved in CD30 promoter induction in ALCL and H-RS cells.
Lymphomas with CD30 overexpression can be divided into four major categories, HL, systemic ALCL NPM-ALK(+), systemic ALCL NPM-ALK(À), and cutaneous ALCL NPM-ALK(À). We recently reported that blockade of the constitutive CD30-TRAF-NF-nB pathway by oncoprotein NPM-ALK is responsible for absence of NF-nB activation in systemic ALCL, NPM-ALK(+) as further evidence that this lymphoma represents a unique entity among CD30-overexpressing lymphomas (21) . The results obtained in this study suggest an autoregulatory mechanism by which levels of CD30 promoter activity are controlled by CD30-ERK1/2 MAPK signaling.
CD30-ERK1/2 MAPK signals induce JunB expression that maintains high levels of the CD30 promoter in ALCL and H-RS cells. This autoregulatory mechanism of CD30 expression is common to ALCL and HL, although the outcome of CD30 signaling between ALCL NPM-ALK(+) and other lymphomas-HL, ALCL NPM-ALK(À), and cutaneous ALCL is different, as we recently reported (Fig. 6) . However, this amplifying loop does not seem to exist in normal cells because the expression level of CD30 on activated lymphocytes is too weak to transduce self-activating signals and effects of CD30 cross-linking are transient (data not shown). Some negative feedback systems may prevent unregulated CD30 activation in nonmalignant lymphocytes.
In conclusion, although both JunB and c-Jun are constitutively expressed in ALCL and H-RS cells, JunB activates the CD30 promoter through the AP-1 site. JunB expression is induced by CD30 signals through an ERK1/2 MAPK pathway and contributes to high levels of constitutive expression of CD30. Thus, ALCL tumor cells and H-RS cells share a common mechanism for CD30 promoter activation.
